Abstract
Chemoinfectomics (chemical infectomics) is the study of small exogenous molecules that are highly specified to define molecular targets (e.g., genes, proteins, glycans, and lipids) or infectomic signatures, to enable functional analysis of microbes and their hosts, and to uncover new antimicrobial drug leads. It requires multidisciplinary expertise in chemical omics (chemogenomics, chemoproteomics, chemoglycomics and chemolipidomics), infectious diseases, and computational sciences (bioinformatics, cheminformatics, large scale statistics and machine learning methods). Chemoinfectomics will overcome the major limitation of the conventional paradigm of managing infectious diseases, which has mainly targeted on microorganisms with low selectivity. The development of drug resistance to both pathogenic and nonpathogenic microbes has been one of the most serious disadvantages of the traditional microbe-directed drug targeting strategies. Therefore, a new chemoinfectomics-based drug discovery paradigm has emerged, focusing on identifying and targeting host factors essential for microbial interactions and pathogenesis. Innovative strategies combining chemoinfectomics, computational biology, and conventional targeting of microbial virulence factors have the potential to greatly augment the protective host factors and to specifically and efficiently eliminate the invading pathogen.
Keywords: Activity-based profiling (ABP), chemogenomics, chemoglycomics, chemoinfectiomics, chemolipidomics, chemoproteomics, infectomes, miroarrays, multidrug resistance (MDR).
Anti-Infective Agents
Title:Chemoinfectomics in Drug Design and Development
Volume: 11 Issue: 2
Author(s): Sheng-He Huang, Hongwei Xia, Feng Chi, Naila K. Khalaf and Ambrose Jong
Affiliation:
Keywords: Activity-based profiling (ABP), chemogenomics, chemoglycomics, chemoinfectiomics, chemolipidomics, chemoproteomics, infectomes, miroarrays, multidrug resistance (MDR).
Abstract: Chemoinfectomics (chemical infectomics) is the study of small exogenous molecules that are highly specified to define molecular targets (e.g., genes, proteins, glycans, and lipids) or infectomic signatures, to enable functional analysis of microbes and their hosts, and to uncover new antimicrobial drug leads. It requires multidisciplinary expertise in chemical omics (chemogenomics, chemoproteomics, chemoglycomics and chemolipidomics), infectious diseases, and computational sciences (bioinformatics, cheminformatics, large scale statistics and machine learning methods). Chemoinfectomics will overcome the major limitation of the conventional paradigm of managing infectious diseases, which has mainly targeted on microorganisms with low selectivity. The development of drug resistance to both pathogenic and nonpathogenic microbes has been one of the most serious disadvantages of the traditional microbe-directed drug targeting strategies. Therefore, a new chemoinfectomics-based drug discovery paradigm has emerged, focusing on identifying and targeting host factors essential for microbial interactions and pathogenesis. Innovative strategies combining chemoinfectomics, computational biology, and conventional targeting of microbial virulence factors have the potential to greatly augment the protective host factors and to specifically and efficiently eliminate the invading pathogen.
Export Options
About this article
Cite this article as:
Huang Sheng-He, Xia Hongwei, Chi Feng, Khalaf Naila K. and Jong Ambrose, Chemoinfectomics in Drug Design and Development, Anti-Infective Agents 2013; 11 (2) . https://dx.doi.org/10.2174/2211352511311020003
DOI https://dx.doi.org/10.2174/2211352511311020003 |
Print ISSN 2211-3525 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-3533 |
Call for Papers in Thematic Issues
An Overview of Drugs for Multiple Targets and Variants of SARS-CoV-2 Through Artificial Intelligence, Machine Learning, Deep Learning, and Experimental Analysis
The emergence and rapid evolution of SARS-CoV-2 variants have posed significant challenges in the ongoing fight against the COVID-19 pandemic. The development of effective treatments for multiple viral targets and variants demands innovative approaches, including artificial intelligence (AI), machine learning (ML), and deep learning (DL) techniques. This special issue aims ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Magnetic Resonance Imaging of Short T2 Relaxation Components in Tissue Using Ultrashort Echo Time (UTE) Pulse Sequences
Current Medical Imaging Docking Studies for Multi-Target Drugs
Current Drug Targets Listeria-Based Anti-Infective Vaccine Strategies
Recent Patents on Anti-Infective Drug Discovery Nose to Brain Delivery of Nanoformulations for Neurotherapeutics in Parkinson’s Disease: Defining the Preclinical, Clinical and Toxicity Issues
Current Drug Delivery Pharmacotherapy of Sickle Cell Disease in Children
Current Pharmaceutical Design Human Kallikrein 6 Cerebrospinal Levels are Elevated in Multiple Sclerosis
Current Drug Discovery Technologies The Seattle Structural Genomics Center for Infectious Disease (SSGCID)
Infectious Disorders - Drug Targets Meta-analysis Identifies Tumor Necrosis Factor-alpha and Interleukin-1 beta as Diagnostic Biomarkers for Bacterial and Aseptic Meningitis
Current Neurovascular Research Delivery Systems of Opioid Analgesics for Pain Relief: A Review
Current Pharmaceutical Design Lysosomal Storage Diseases and the Blood-Brain Barrier
Current Pharmaceutical Design Recent Patents in Cell Therapy for Amyotrophic Lateral Sclerosis
Recent Patents on Regenerative Medicine Metallic Colloid Nanotechnology, Applications in Diagnosis and Therapeutics
Current Pharmaceutical Design Cancer-Homing Toxins
Current Pharmaceutical Design Targeted Delivery for Neurodegenerative Disorders Using Gene Therapy Vectors: Gene Next Therapeutic Goals
Current Gene Therapy Nanoparticles in the Pharmaceutical Industry and the Use of Supercritical Fluid Technologies for Nanoparticle Production
Current Drug Delivery Role of Chemokines and Trafficking of Immune Cells in Parasitic Infections
Current Immunology Reviews (Discontinued) A Review on Exploring Better Safety Prospects in Managing Cancer using Liposomal Combinations of Food Bioactive Compounds and Anticancer Drugs: Combisomes
Current Drug Delivery Nitrones: A Potential New Alternative as Therapeutic Agents
Current Organic Chemistry Fungal Bioactive Compounds in Pharmaceutical Research and Development
Current Bioactive Compounds Melatonin Metabolism in the Central Nervous System
Current Neuropharmacology